Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: A randomized phase II study

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 2, 2011, Pages 430-439

  Rostaing, Lionel ^a   Massari, Pablo ^b   Garcia, Valter Duro ^c   Mancilla Urrea, Eduardo ^d   Nainan, Georgy ^e   Rial, Maria Del Carmen ^f   Steinberg, Steven ^g   Vincenti, Flavio ^h   Shi, Rebecca ⁱ   Di Russo, Greg ⁱ   Thomas, Dolca ⁱ   Grinyó, Josep ^j  

^a INSERM   (France)

^b HOSPITAL PRIVADO   (Argentina)

^c Hospital Dom Vicente Scherer   (Brazil)

^d INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^e Lakeshore Hospital   (India)

^f Instituto de Nefrologia Buenos Aires ar   (Argentina)

^g SHARP MEMORIAL HOSPITAL   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ BRISTOL MYERS SQUIBB   (United States)

^j HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BELATACEPT; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; HLA ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BASAL CELL CARCINOMA; CHICKENPOX; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATALITY; FEMALE; FEVER; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; GRAFT SURVIVAL; HERPES SIMPLEX; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; ONYCHOMYCOSIS; OPEN STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; SKIN CANDIDIASIS; SKIN INFECTION; SURVIVAL; TINEA CORPORIS; TINEA CRURIS; TINEA VERSICOLOR; URINARY TRACT INFECTION; VULVOVAGINITIS;

ACUTE DISEASE; ADULT; BIOPSY; CALCINEURIN; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TIME FACTORS; TREATMENT OUTCOME;

EID: 79951933190     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05840710     Document Type: Article

References (36)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B: Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 4: 378-383, 2004 (Pubitemid 38282293)
2. Naesens M, Kuypers DR, Sarwal M: Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4: 481-508, 2009
3. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR: The natural history of chronic allograft nephropathy. N Engl J Med 349: 2326-2333, 2003 (Pubitemid 37509740)
4. Ducloux D, Motte G, Kribs M, Abdelfatah AB, Bresson-Vautrin C, Rebibou JM, Chalopin JM: Hypertension in renal transplantation: Donor and recipient risk factors. Clin Nephrol 57: 409-413, 2002 (Pubitemid 34625047)
5. Mathis AS, Dave N, Knipp GT, Friedman GS: Drugrelated dyslipidemia after renal transplantation. Am J Health Syst Pharm 61: 565-585, 2004
6. Roland M, Gatault P, Doute C, Buchler M, Al Najjar A, Barbet C, Chatelet V, Marliere JF, Nivet H, Lebranchu Y, Halimi JM: Immunosuppressive medications, clinical and metabolic parameters in new-onset diabetes mellitus after kidney transplantation. Transpl Int 21: 523-530, 2008 (Pubitemid 351600064)
7. Vincenti F, Friman S, Scheuermann E, Rostaing L, Jenssen T, Campistol JM, Uchida K, Pescovitz MD, Marchetti P, Tuncer M, Citterio F, Wiecek A, Chadban S, El Shahawy M, Budde K, Goto N: Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant 7: 1506-1514, 2007 (Pubitemid 46776239)
8. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP: Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 62: 311-318, 2002 (Pubitemid 34754077)
9. Meier-Kriesche HU, Baliga R, Kaplan B: Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 75: 1291-1295, 2003 (Pubitemid 36513036)
10. Meier-Kriesche HU, Schold JD, Kaplan B: Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 4: 1289-1295, 2004
11. Wyeth: Rapamune® Prescribing Information. Available at: www.Wyeth.com. Accessed March 10, 2010
12. Stallone G, Infante B, Grandaliano G, Gesualdo L: Management of side effects of sirolimus therapy. Transplantation 87: S23-S26, 2009
13. Novartis: Zortress® Prescribing Information. Available at: http://www.pharma.us.novartis.com. Accessed May 12, 2010
14. Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G, Lang P, Grinyo J, Halloran PF, Solez K, Hagerty D, Levy E, Zhou W, Natarajan K, Charpentier B: Costimulation blockade with belatacept in renal transplantation. N Engl J Med 353: 770-781, 2005 (Pubitemid 41215486)
15. Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, Massari P, Mondragon-Ramirez GA, Agarwal M, Di Russo G, Lin CS, Garg P, Larsen CP: A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 10: 535-546, 2010
16. Durrbach A, Pestana JM, Pearson T, Vincenti F, Garcia VD, Campistol J, Rial MC, Florman S, Block A, Di Russo G, Xing J, Garg P, Grinyo J: A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 10: 547-557, 2010
17. Abouljoud MS, Kumar MS, Brayman KL, Emre S, Bynon JS: Neoral rescue therapy in transplant patients with intolerance to tacrolimus. Clin Transplant 16: 168-172, 2002 (Pubitemid 34746392)
18. Mohsin N, Pakkyara A, Budruddin M, Obaid F, Kumar A, Malvathu S, Kalankara S, Amitabh A, Daar A: Low tacrolimus dose requirements in renal transplant recipients in the omani population: Implications for pharmacogenetics? Transplant Proc 37: 2911-2912, 2005
19. Saber LT, Ikeda MY, Almeida JM: Posttransplantation conversion to sirolimus-based immunosuppression: A single center experience. Transplant Proc 39: 3098-3100, 2007 (Pubitemid 350251400)
20. Levey AS, Greene T, Schluchter MD, Cleary PA, Teschan PE, Lorenz RA, Molitch ME, Mitch WE, Siebert C, Hall PM: Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol 4: 1159-1171, 1993
21. Vincenti F, Schena FP, Paraskevas S, Hauser IA, Walker RG, Grinyo J: A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 8: 307-316, 2008
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130: 461-470, 1999 (Pubitemid 29135798)
23. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, Croker BP, Demetris AJ, Drachenberg CB, Fogo AB, Furness P, Gaber LW, Gibson IW, Glotz D, Goldberg JC, Grande J, Halloran PF, Hansen HE, Hartley B, Hayry PJ, Hill CM, Hoffman EO, Hunsicker LG, Lindblad AS, Yamaguchi Y: The Banff 97 working classification of renal allograft pathology. Kidney Int 55: 713-723, 1999 (Pubitemid 29082898)
24. Pei R, Wang G, Tarsitani C, Rojo S, Chen T, Takemura S, Liu A, Lee J: Simultaneous HLA Class I and Class II antibodies screening with flow cytometry. Hum Immunol 59: 313-322, 1998 (Pubitemid 28225990)
25. Pei R, Lee JH, Shih NJ, Chen M, Terasaki PI: Single human leukocyte antigen flow cytometry beads for accurate identification of human leukocyte antigen antibody specificities. Transplantation 75: 43-49, 2003 (Pubitemid 36139693)
26. Vaidya S, Cooper TY, Avandsalehi J, Barnes T, Brooks K, Hymel P, Noor M, Sellers R, Thomas A, Stewart D, Daller J, Fish JC, Gugliuzza KK, Bray RA: Improved flow cytometric detection of HLA alloantibodies using pronase: Potential implications in renal transplantation. Transplantation 71: 422-428, 2001 (Pubitemid 32175980)
27. Watson CJ, Firth J, Williams PF, Bradley JR, Pritchard N, Chaudhry A, Smith JC, Palmer CR, Bradley JA: A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 5: 2496-2503, 2005
28. Pallardo LM, Oppenheimer F, Guirado L, Conesa J, Hortal LJ, Romero R, Rivero M, de Bonis E, Muniz ML, Esforzado N: Calcineurin inhibitor reduction based on maintenance immunosuppression with mycophenolate mofetil in renal transplant patients: POP study. Transplant Proc 39: 2187-2189, 2007 (Pubitemid 47418193)
29. Schena FP, Pascoe MD, Alberu J, del Carmen RM, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF: Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87: 233-242, 2009
30. Vincenti F, Blancho G, Durrbach A, Friend P, Grinyo J, Halloran P, Klempnauer J, Lang P, Larsen C, Muhlbacher F, Nashan B, Soulillou JP, Vanrenterghem Y, Wekerle T, Agarwal M, Gujrathi S, Shen J, Shi R, Townsend R, Charpentier B: Five-year results of a phase II study with belatacept in renal transplantation. J Am Soc Nephrol 21: 1587-1596, 2010
31. Ekberg H, Bernasconi C, Tedesco-Silva H, Vitko S, Hugo C, Demirbas A, Acevedo RR, Grinyo J, Frei U, Vanrenterghem Y, Daloze P, Halloran P: Calcineurin inhibitor minimization in the Symphony study: Observational results 3 years after transplantation. Am J Transplant 9: 1876-1885, 2009
32. Gonzalez MM, Morales JM, Marcen R, Campistol JM, Oppenheimer F, Seron D, Gil-Vernet S, Capdevila L, Andres A, Lampreave I, Del Castillo D, Cabello M, Burgos D, Valdes F, Anaya F, Escuin F, Arias M, Pallardo L, Bustamante J: Renal function in patients with cadaveric kidney transplants treated with tacrolimus or cyclosporine. Transplant Proc 39: 2167-2169, 2007 (Pubitemid 47432698)
33. Solez K, Vincenti F, Filo RS: Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tarolimus versus cyclosporine: a report of the FK506 Kidney Transplant Study Group. Transplantation 66: 1736-1740, 1998 (Pubitemid 29035001)
34. Abramowicz D, Manas D, Lao M, Vanrenterghem Y, Del Castillo D, Wijngaard P, Fung S: Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: A randomized, controlled study. Transplantation 74: 1725-1734, 2002 (Pubitemid 36019327)
35. MacPhee IA, Bradley JA, Briggs JD, Junor BJ, MacPherson SG, McMillan MA, Rodger RS, Watson MA: Long-term outcome of a prospective randomized trial of conversion from cyclosporine to azathioprine treatment one year after renal transplantation. Transplantation 66: 1186-1192, 1998 (Pubitemid 28530323)
36. Waid T: Tacrolimus as secondary intervention vs. cyclosporine continuation in patients at risk for chronic renal allograft failure. Clin Transplant 19: 573-580, 2005